We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Subcutaneous and Intranasal Administration of RA 27/3 Rubella Vaccine Alone and in Conjunction With Live Attenuated Measles Vaccine

Simin Saidi, VMD, MPH; Kiarash Naficy, MD
Am J Dis Child. 1969;118(2):209-212. doi:10.1001/archpedi.1969.02100040211009.
Text Size: A A A
Published online


THE RA 27/3 strain of rubella vaccine isolated from a tissue explant of fetal kidney derived from conceptus of a rubellainfected mother and attenuated after several passages in WI-38 human fibroblast tissue culture has been shown in several clinical trials to be effective for induction of sero-immunity when administered subcutaneously as well as intranasally, with no transmission to sero-negative contacts.1-3 To the best of our knowledge, RA 27/3 has not been used simultaneously with other vaccines. This communication presents our findings on subcutaneous and intranasal administration of RA 27/3 rubella vaccine, alone and in conjunction with live attenuated measles vaccine.

Materials and Methods  Vaccine.—The RA 27/3 rubella vaccine (batch AR/2/2A) was obtained with 102.8 TCID50 titer by monkey kidney interference method. Measles vaccine (Schwarz strain) in 20 dose vials with the titer of 102.8 TCID50 in chick embryo fibroblast was used.Antigens.—Measles and


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.